hepatobiliary and pancreatic malignancies
Conditions
Interventions
Case series:None
Sponsors
SIR Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. Patients with hepatobiliary and pancreatic malignancies diagnosed by histopathological or cytological examinations (Patients with primary liver cancer can meet the clinical diagnostic criteria of the "Diagnosis and Treatment Specifications for Primary Liver Cancer" (2019 Edition)); 3. According to the RECIST 1.1 standard, there is at least one measurable target lesion; 4. The physician believes that it may benefit from carrelizumab treatment and voluntarily accepts the treatment; 5. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Women during pregnancy or lactation; 2. Patients who have hypersensitivity to the active ingredient of carrelizumab or any of the excipients listed in [ingredients]; 3. Participate in any research with intervention measures outside of routine clinical practice; 4. The investigator judges other conditions that may affect the conduct of clinical research and the determination of research results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;progression-free survival;disease control rate;overall survival;Objective Duration of Remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety; | — |
Countries
China
Contacts
Public ContactCai Liuxin
Run Run Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed